Trial Profile
A retrospective study of metastatic renal cell cancer patients with slight progression but still a stable disease treated with an escalated dose of sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 20 Sep 2018 New trial record